---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027332"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2026-08-12T20:27:08+00:00"
generated_at: "2026-08-12T20:28:16.695523+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioCardia Q2 net loss narrows to $1.6M; PMDA supports CardiAMP Japan filing

## Summary
- Q2 2026 net loss $1.6M vs $2.0M year-ago; H1 loss $3.9M vs $4.8M.
- R&D expense down to $0.9M from $1.4M; cash $4.1M, runway into 2027.
- Raised ~$4.9M net proceeds from ATM facility in Q2.
- Japan PMDA supports Shonin submission for CardiAMP; filing targeted Q4 2026.
- FDA confirms CardiAMP HF II trial may support PMA; Helix DeNovo approval possible.

## SEC filing metadata
- accession: 0001437749-26-027332
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2026-08-12T20:27:08+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774926027332/0001437749-26-027332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774926027332/bcda20260812_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027332
- JSON: https://secwatch.observer/filing/0001437749-26-027332.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.